<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00889291</url>
  </required_header>
  <id_info>
    <org_study_id>1-Abbs</org_study_id>
    <nct_id>NCT00889291</nct_id>
  </id_info>
  <brief_title>HeRO Vascular Access Device Post Market Procedural Survey Protocol</brief_title>
  <acronym>PPS</acronym>
  <official_title>HeRO Vascular Access Device Post Market Procedural Survey Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merit Medical Systems, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merit Medical Systems, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post market observational survey of a vascular access device for access-challenged patients.
      Data collection efforts focused on patient medical and access history and implant procedure
      results.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluation Design: This is a multi-center post market observational survey designed to
      collect procedural data on a minimum of 50 HeRO™ patients in the commercialization phase.
      Data will be collected retrospectively for patients already implanted with the HeRO™ device
      in the commercialization phase or prospectively for patients that receive the HeRO™ Device
      during the data collection period. No special patient screening, testing, or procedures are
      required. There is no required patient follow-up.

      Subject Population: Any patients the investigator deems/deemed eligible for HeRO™ implant
      with complete procedural data are eligible for inclusion in this post market observational
      survey.

      Endpoints: None

      Inclusion/Exclusion Criteria: There are no formal screening criteria other than patients must
      have all required procedural data points available for recording on the case report form.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Device placement success</measure>
    <time_frame>End of procedure</time_frame>
  </primary_outcome>
  <enrollment type="Actual">77</enrollment>
  <condition>End Stage Renal Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        End stage renal disease patients requiring vascular access
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Glickman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sentara Heart Hospital, Norfolk, VA</affiliation>
  </overall_official>
  <link>
    <url>http://www.hemosphere.net/</url>
    <description>Additional information regarding the HeRO Vascular Access Device</description>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2009</study_first_submitted>
  <study_first_submitted_qc>April 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2009</study_first_posted>
  <last_update_submitted>August 7, 2017</last_update_submitted>
  <last_update_submitted_qc>August 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>End stage renal disease</keyword>
  <keyword>Bacteremia</keyword>
  <keyword>HeRO Vascular Access Device</keyword>
  <keyword>Access challenged</keyword>
  <keyword>Catheter dependent</keyword>
  <keyword>End stage renal disease requiring vascular access. See HeRO device instructions for use for appropriate patient population</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

